Dyne Therapeutics, Inc. — fact timeline

Barry E. Greene was elected as Class I director at Dyne Therapeutics, Inc..

“On June 22, 2026, the Board of Directors (the “Board”) of Dyne Therapeutics, Inc. (the “Company”), upon recommendation from the Nominating and Corporate Governance Committee of the Board, elected Barry E. Greene as a Class I director to serve on the Board until the Company’s 2027 Annual Meeting of Stockholders and until his successor has been duly elected and qualified or until his earlier death, resignation or removal.”

Dyne Therapeutics, Inc. incurred term loan of $50.0 million with Hercules Capital, Inc..

“the Company borrowed one of the additional loan tranches in an aggregate principal amount of $50.0 million on the Amendment Closing Date.”

Dyne Therapeutics, Inc. amended credit facility of $50.0 million with Hercules Capital, Inc. at Wall Street Journal prime rate, subject to a floor of 7.50%, plus 2.45% maturing July 1, 2030.

“the Second Amendment expanded the debt facility to an aggregate of up to $400.0 million by adding two additional tranches of $50.0 million each and increasing the final tranche by $25.0 million, and reduced the minimum cash covenant under the Loan Agreement. Pursuant to the Second Amendment, the Company borrowed one of the additional loan tranches in an aggregate principal amount of $50.0 million on the Amendment Closing Date.”

Dyne Therapeutics, Inc. amended Second Amendment with Hercules Capital, Inc., as administrative agent and collateral agent, and certain other financial institutions as lenders valued at $400.0 million (effective 2026-06-16).

“On June 16, 2026 (the “Amendment Closing Date”), Dyne Therapeutics, Inc. (the “Company”) entered into the Second Amendment (the “Second Amendment”) to its Loan and Security Agreement with Hercules Capital, Inc., in its capacity as administrative agent and collateral agent (the “Agent”), and certain other financial institutions party thereto as lenders (collectively, the “Lenders”), dated as of June 27, 2025 (the “Initial Loan Agreement” and as amended by the First Amendment to Loan and Security Agreement dated as of December 8, 2025 and the Second Amendment, the “Loan Agreement”).”

Dyne Therapeutics, Inc. shareholders approved Ratification of Deloitte & Touche LLP as independent registered public accounting firm for fiscal year ending December 31, 2026 at the 2026-06-05 meeting.

“The stockholders of the Company ratified the appointment of Deloitte & Touche LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2026.”

Dyne Therapeutics, Inc. shareholders approved Approval of amendment to restated certificate of incorporation to provide for officer exculpation at the 2026-06-05 meeting.

“The stockholders of the Company approved an amendment to the Company’s restated certificate of incorporation to provide for officer exculpation (the “Officer Exculpation Amendment”).”

Dyne Therapeutics, Inc. shareholders approved Approval of amendment to restated certificate of incorporation to increase authorized common stock from 200,000,000 to 400,000,000 shares at the 2026-06-05 meeting.

“The stockholders of the Company approved an amendment to the Company’s restated certificate of incorporation to increase the number of authorized shares of common stock from 200,000,000 shares to 400,000,000 shares (the “Authorized Shares Amendment”).”

Dyne Therapeutics, Inc. shareholders approved Non-binding advisory vote on executive compensation at the 2026-06-05 meeting.

“The stockholders of the Company approved, on a non-binding advisory basis, the compensation of the Company’s named executive officers.”

Dyne Therapeutics, Inc. shareholders approved Election of Class III directors at the 2026-06-05 meeting.

“The stockholders of the Company elected David Lubner, Brian Posner and Jason Rhodes as Class III directors, each to serve for a three-year term expiring at the 2029 annual meeting of stockholders and until his respective successor has been duly elected and qualified.”

Dyne Therapeutics, Inc. reported financial results for the first quarter of 2026.

“Dyne Therapeutics, Inc. (Nasdaq: DYN), a clinical-stage company focused on delivering functional improvement for people living with genetically driven neuromuscular diseases, today reported financial results for the first quarter of 2026 and recent business highlights.”

Dyne Therapeutics, Inc. entered into Underwriting Agreement with Morgan Stanley & Co. LLC, Jefferies LLC, Stifel, Nicolaus & Company, Incorporated and Guggenheim Securities, LLC, as representatives of the several underwriters valued at approximately $328.5 million (effective 2025-12-09).

“On December 9, 2025, Dyne Therapeutics, Inc. (the “Company”) entered into an underwriting agreement (the “Underwriting Agreement”) with Morgan Stanley & Co. LLC, Jefferies LLC, Stifel, Nicolaus & Company, Incorporated and Guggenheim Securities, LLC, as representatives of the several underwriters named therein (the “Underwriters”), relating to an underwritten public offering (the “Offering”) of 18,980,478 shares (the “Underwritten Shares”) of the Company’s common stock, par value $0.0001 per share (the “Common Stock”).”

Dyne Therapeutics, Inc. incurred term loan of $50.0 million with Hercules Capital, Inc. at Wall Street Journal prime rate, subject to a floor of 7.50%, plus 2.45% maturing July 1, 2030.

“On December 8, 2025 (the “Amendment Closing Date”), Dyne Therapeutics, Inc. (the “Company”) entered into the First Amendment (the “First Amendment”) to Loan and Security Agreement with Hercules Capital, Inc. (“Hercules”), in its capacity as administrative agent and collateral agent (the “Agent”), and certain other financial institutions party thereto as lenders (collectively, the “Lenders”). The First Amendment amended certain of the tranche sizes and funding milestone requirements under the Loan and Security Agreement, dated as of June 27, 2025 (the “Initial Loan Agreement” and, such Initial Loan Agreement as amended by the First Amendment, the “Loan Agreement”), by and among the Company, Hercules and the Lenders and permitted the Company to borrow, as of the Amendment Closing Date, a second term loan tranche in an aggregate principal amount of $50.0 million. Following entry into the First Amendment and the borrowing of the second term loan tranche, the Company has two additional term”

Dyne Therapeutics, Inc. incurred credit facility of up to $275.0 million with Hercules Capital, Inc. at Wall Street Journal prime rate, subject to a floor of 7.50%, plus 2.45% maturing July 1, 2030.

“The Loan Agreement provides for term loans in an aggregate principal amount of up to $275.0 million under multiple tranches”

Erick Lucera was appointed as Chief Financial Officer and Treasurer at Dyne Therapeutics, Inc..

“On March 20, 2025, Dyne Therapeutics, Inc. (the “Company”) announced that its Board of Directors (the “Board”) had appointed Erick Lucera as Chief Financial Officer and Treasurer of the Company, effective as of March 31, 2025 (the “Effective Date”).”

Susanna High resigned as Chief Operating Officer at Dyne Therapeutics, Inc..

“Jonathan McNeill, M.D., the Company’s Chief Business Officer, and Susanna High, the Company’s Chief Operating Officer, each notified the Company of their intention to resign their employment.”

Jonathan McNeill, M.D. resigned as Chief Business Officer at Dyne Therapeutics, Inc..

“Jonathan McNeill, M.D., the Company’s Chief Business Officer, and Susanna High, the Company’s Chief Operating Officer, each notified the Company of their intention to resign their employment.”

Dyne Therapeutics, Inc. reported the quarter ended March 31, 2024 results: net income $65.6 million, or $0.81 per basic and diluted share, EPS $0.81 per basic and diluted share.

“Net loss for the quarter ended March 31, 2024 was $65.6 million, or $0.81 per basic and diluted share.”

Joshua Brumm departed as Chief Executive Officer at Dyne Therapeutics, Inc..

“succeeding Joshua Brumm”

John Cox was elected as Class I Director at Dyne Therapeutics, Inc..

“Mr. Cox was elected as a Class I director”

John Cox was appointed as President and Chief Executive Officer at Dyne Therapeutics, Inc..

“had appointed John Cox as President and Chief Executive Officer of the Company succeeding Joshua Brumm”

Dyne Therapeutics, Inc. reported the fourth quarter and full year 2023 results: net income Net loss for the quarter ended December 31, 2023 was $66.6 million, or $1.09 per basic and diluted share, EPS $1.09 per basic and diluted share.

“Dyne Therapeutics, Inc . (Nasdaq: DYN), a clinical-stage muscle disease company focused on advancing innovative life-transforming therapeutics for people living with genetically driven diseases, today reported financial results for the fourth quarter and full year 2023 and recent business highlights.”

Dyne Therapeutics, Inc. reported September 30, 2023 results: net income Net loss for the quarter ended September 30, 2023 was $60.2 million, or $0.99 per basic and diluted share., EPS $0.99.

“Net loss for the quarter ended September 30, 2023 was $60.2 million, or $0.99 per basic and diluted share.”

Dyne Therapeutics, Inc. reported the quarter ended June 30, 2023 results: net income $64.9 million, EPS $1.08 per basic and diluted share.

“Net loss for the quarter ended June 30, 2023 was $64.9 million, or $1.08 per basic and diluted share.”

Dyne Therapeutics, Inc. shareholders approved Ratification of appointment of Deloitte & Touche LLP as independent registered public accounting firm for fiscal year ending December 31, 2023 at the 2023-05-24 meeting.

“b) The stockholders of the Company ratified the appointment of Deloitte & Touche LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2023. The results of the stockholders’ vote with respect to such matter were as follows: For Against Abstain 44,199,721 2,413 3”

Dyne Therapeutics, Inc. shareholders approved Election of three Class III directors: Joshua Brumm, David Lubner, and Jason Rhodes at the 2023-05-24 meeting.

“The stockholders of the Company elected Joshua Brumm, David Lubner and Jason Rhodes as Class III directors, each to serve for a three-year term expiring at the 2026 annual meeting of stockholders and until his respective successor has been duly elected and qualified. The results of the stockholders’ vote with respect to such matter were as follows: Name For Withheld Broker Non-Votes Joshua Brumm 35,497,922 6,780,619 1,923,596 David Lubner 32,530,452 9,748,089 1,923,596 Jason Rhodes 28,522,828 13,755,713 1,923,596”

Dr. Lawrence Klein resigned as member of the Board of Directors at Dyne Therapeutics, Inc..

“On May 24, 2023, Dr. Lawrence Klein notified Dyne Therapeutics, Inc. (the “Company”) of his decision to resign as a member of the Board of Directors of the Company, effective immediately.”

Dyne Therapeutics, Inc. reported the quarter ended March 31, 2023 results: net income Net loss for the quarter ended March 31, 2023 was $44.2 million, or $0.78 per basic and diluted share., EPS $0.78 per basic and diluted share.

“Net loss for the quarter ended March 31, 2023 was $44.2 million, or $0.78 per basic and diluted share.”

Dyne Therapeutics, Inc. reported the year ended December 31, 2022 results: net income Net loss for the year ended December 31, 2022 was $168.1 million, or $3.23 per basic and diluted share., EPS $3.23 per basic and diluted share.

“Net loss for the year ended December 31, 2022 was $168.1 million, or $3.23 per basic and diluted share.”

Dyne Therapeutics, Inc. reported the quarter ended December 31, 2022 results: net income Net loss for the quarter ended December 31, 2022 was $38.8 million, or $0.74 per basic and diluted share., EPS $0.74 per basic and diluted share.

“Net loss for the quarter ended December 31, 2022 was $38.8 million, or $0.74 per basic and diluted share.”

Dyne Therapeutics, Inc. reported the third quarter of 2022 results: net income Net loss for the quarter ended September 30, 2022 was $41.4 million, or $0.80 per basic and diluted share., EPS $0.80 per basic and diluted share.

“Net loss for the quarter ended September 30, 2022 was $41.4 million, or $0.80 per basic and diluted share.”

Carlo Incerti was elected as Director at Dyne Therapeutics, Inc..

“On March 2, 2022, the Board of Directors (the “Board”) of Dyne Therapeutics, Inc. (the “Company”), upon recommendation from the Nominating and Corporate Governance Committee of the Board, elected Carlo Incerti, M.D. as a Class I director to serve on the Board until the Company’s 2024 Annual Meeting of Stockholders and until his successor has been duly elected and qualified or until his earlier death, resignation or removal.”